The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

中文翻译：

---

靶向翻译：eIF4E 作为新兴抗癌药物靶点

翻译起始因子 eIF4E 介导一个限速过程，该过程驱动许多致癌蛋白（例如细胞周期蛋白 D1、存活蛋白和 VEGF）的选择性翻译，从而促进肿瘤生长、转移和治疗耐药性。作为癌症信号网络中必不可少的监管中心，许多致癌信号通路似乎都集中在 eIF4E 上。因此，靶向 eIF4E 介导的帽依赖性翻译被认为是一种有前途的抗癌策略。本文回顾了可用于针对 eIF4E 的策略，重点介绍了在每个不同级别针对 eIF4E 活动的代理。